Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant

Next Previous
Trial Profile

Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Relacorilant (Primary)
  • Indications Cushing syndrome
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms GRACE
  • Sponsors Corcept Therapeutics

    • Most Recent Events

    • 22 Apr 2024 Primary endpoint (In patients with hypertension, the proportion of patients with a loss of response with respect to hypertension from visit OL22 to RW12) has been met, according to a Corcept Therapeutics media release.
    • 22 Apr 2024 According to a Corcept Therapeutics media release, company plan to present data from the open-label and randomized withdrawal phases at a medical conference in June and remain on track to submit NDA this quarter.
    • 22 Apr 2024 Results from the open-label portion this trial presented in a Corcept Therapeutics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top